Diabetes and endocrinology specialists at Riley Children’s Health deliver expert care for infants, children and adolescents with diabetes and other endocrine disorders. Our board certified physicians have completed additional subspecialty training in pediatric endocrinology and pediatric diabetology. Ten certified diabetes and education specialists provide a wide range of resources and support to patients and their families. DIABETES & ENDOCRINOLOGY
Professional organization affiliations VICE CHAIR Type 1 Diabetes TrialNet > Linda A. DiMeglio, MD, MPH SECRETARY Pediatric Endocrine Society > Erica A. Eugster, MD CHAIR, PEDIATRIC ENDOCRINOLOGY SUBBOARD American Board of Pediatrics > John S. Fuqua, MD CHAIR, TYPE 2 DIABETES WORKING GROUP Type 1 Diabetes Exchange Quality Improvement Collaborative > Tamara S. Hannon, MD CO-CHAIR BRAINY-T1D Consortium > Linda A. DiMeglio, MD, MPH ASSOCIATE EDITOR Diabetes Care > Emily K. Sims, MD
RESEARCH HIGHLIGHTS
■ Collaborating with the Herman B Wells Center for Pediatric Research , Riley
17 active research studies
Children’s is a research study site for novel endocrine and diabetes therapies to address precocious puberty, Turner syndrome, Noonan syndrome, growth hormone deficiency and Type 2 diabetes.
■ Riley Children’s is one of 17 international centers participating in TrialNet , a major research network focused on Type 1 diabetes prevention and treatment. ■ Our investigators are also involved in studies of the microbiome in Type 1 diabetes, as well as research related to new technologies and therapeutics. We are engaged in clinical trials for therapies designed to modify the course of Type 1 diabetes: ■ TADPOL (Targeting Type 1 Diabetes via Polyamines) Phase II study evaluating the efficacy and safety of difluoromethylornithine ■ WAVE T1D Phase I/II trial evaluating anti-thymocyte globulin followed by adalimumab or verapamil
Premier programs
TOP DISTINCTIONS
Riley Children’s hosted the 2025 CARES Foundation Annual Patient Education Conference focused on CAH. The event brought together more than 200 patients, family members, clinicians and researchers from across the United States. The program featured 16 expert speakers who delivered sessions on advances in CAH management, emerging therapies and practical aspects of care. The conference included a Patient Advisory Summit to facilitate collaboration among patients, caregivers and industry
■ Early-Stage Type 1 Diabetes Program ■ Endocrine Diseases Newborn Screening Program (statewide) ■ Youth Diabetes Prevention Program (for children at risk for diabetes) ■ Multidisciplinary programs – Differences of Sex Development Program – Gender Health Program – Late Endocrine Effects of Cancer Therapy Program – Metabolic Bone Disease Program – Muscular Dystrophy Program ■ Young Adult Diabetes Transition Program
■ One of the first pediatric programs in the Midwest (and first in Indiana) to administer teplizumab (the first FDA- approved preventive treatment for Type 1 diabetes) ■ Only comprehensive care center in the Midwest for congenital adrenal hyperplasia (CAH); one of eight Comprehensive Care Centers of Excellence in the nation (designated by the CARES Foundation) ■ Active in clinical and
78 research publications in 2025
NOTABLE PUBLICATIONS
Hormone Research in Paediatrics: December 2025 Prevalence of adrenal pathology in children referred for premature pubarche: A 10-year retrospective review in an Indiana cohort Lancet: October 2025 Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): A randomised, double-blind, placebo-controlled, phase 3 trial Children (Basel, Switzerland): November 2025 Long-term follow-up and risk of PCOS in Indiana girls with a history of premature adrenarche-A single center experience Diabetologia: May 2025 IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes
translational research studies for diabetes and endocrine disorders
partners to inform future therapeutic development.
BY THE NUMBERS
Clinical locations 8
1,800 Diabetes 6,800 Endocrine Patients seen annually +
284 Physicians Years of cumulative experience
181 Advanced practice providers
Authors of recent clinical practice guideline
■ Linda A. DiMeglio, MD, MPH , is co-principal investigator of DiabDocs , a National Institutes of Health (NIH)-funded physician-scientist career development program. ■ Riley Children’s and IU School of Medicine have a leading pediatric endocrinology and diabetology fellowship . ■ Alexander R. Tuttle, MD , and Erika L. Zevin, MD , are co-leaders of the IU site for the Endocrine Society Medical Student Engagement Program. ■ IU School of Medicine leadership: Zeina M. Nabhan, MD , serves as associate dean of graduate medical education. Training the next generation
DIVISION CHIEF Linda A. DiMeglio, MD, MPH Edwin Letzter Professor of Pediatrics, IU School of Medicine > Connect with Dr. DiMeglio on Doximity.
Endocrinologists at Riley Children’s co-authored the Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab in Clinical Practice , published in April 2024.
The diabetes program at Riley Children’s is accredited by the Association of Diabetes Care and Education Specialists.
17 board certified physicians
See full team member list >
Refer a patient online
T 317.944.3889
Made with FlippingBook flipbook maker